DR. EVAN YALE SNYDER, M.D., PHD
Medical Practice at Dickinson St, San Diego, CA

2008024, Oct 2, 2008

Oct 29, 2007

11/980166

Xuejun Huang Parsons - San Diego CA, US
Evan Y. Snyder - San Diego CA, US

The Burnham Institute of Medical Research - La Jolla CA

C12N 5/08, C12N 5/06

435366, 435325, 435363

Stem cells, including mammalian, and particularly primate primordial stem cells (pPSCs) such as human embryonic stem cells (hESCs), hold great promise for restoring cell, tissue, and organ function. However, cultivation of stem cells, particularly undifferentiated hESCs, in serum-free, feeder-free, and conditioned-medium-free conditions remains crucial for large-scale, uniform production of pluripotent cells for cell-based therapies, as well as for controlling conditions for efficiently directing their lineage-specific differentiation. This instant invention is based on the discovery of the formulation of minimal essential components necessary for maintaining the long-term growth of pPSCs, particularly undifferentiated hESCs. Basic fibroblast growth factor (bFGF), insulin, ascorbic acid, and laminin were identified to be both sufficient and necessary for maintaining hESCs in a healthy self-renewing undifferentiated state capable of both prolonged propagation and then directed differentiation. Having discerned these minimal molecular requirements, conditions that would permit the substitution of poorly-characterized and unspecified biological additives and substrates were derived and optimized with entirely defined constituents, providing a “biologics”-free (i.e., animal-, feeder-, serum-, and conditioned-medium-free) system for the efficient long-term cultivation of pPSCs, particularly pluripotent hESCs. Such culture systems allow the derivation and large-scale production of stem cells such as pPSCs, particularly pluripotent hESCs, in optimal yet well-defined biologics-free culture conditions from which they can be efficiently directed towards a lineage-specific differentiated fate in vitro, and thus are important, for instance, in connection with clinical applications based on stem cell therapy and in drug discovery processes.

2005023, Oct 20, 2005

Dec 31, 2004

11/027395

Xuejun Parsons - San Diego CA, US
Evan Snyder - La Jolla CA, US

C12N005/08

435366000, 435404000

Stem cells, including mammalian, and particularly primate primordial stem cells (pPSCs) such as human embryonic stem cells (hESCs), hold great promise for restoring cell, tissue, and organ function. However, cultivation of stem cells, particularly undifferentiated hESCs, in serum-free, feeder-free, and conditioned-medium-free conditions remains crucial for large-scale, uniform production of pluripotent cells for cell-based therapies, as well as for controlling conditions for efficiently directing their lineage-specific differentiation. This instant invention is based on the discovery of the formulation of minimal essential components necessary for maintaining the long-term growth of pPSCs, particularly undifferentiated hESCs. Basic fibroblast growth factor (bFGF), insulin, ascorbic acid, and laminin were identified to be both sufficient and necessary for maintaining hESCs in a healthy self-renewing undifferentiated state capable of both prolonged propagation and then directed differentiation. Having discerned these minimal molecular requirements, conditions that would permit the substitution of poorly-characterized and unspecified biological additives and substrates were derived and optimized with entirely defined constituents, providing a “biologics”-free (i.e., animal-, feeder-, serum-, and conditioned-medium-free) system for the efficient long-term cultivation of pPSCs, particularly pluripotent hESCs. Such culture systems allow the derivation and large-scale production of stem cells such as pPSCs, particularly pluripotent hESCs, in optimal yet well-defined biologics-free culture conditions from which they can be efficiently directed towards a lineage-specific differentiated fate in vitro, and thus are important, for instance, in connection with clinical applications based on stem cell therapy and in drug discovery processes.

2005016, Aug 4, 2005

Sep 22, 2004

10/947407

Evan Snyder - La Jolla CA, US
Karen Aboody - Arcadia CA, US
Xandra Breakefield - Newton Center MA, US
William Lynch - Ravenna OH, US

Children's Medical Center Corporation - Boston MA
The General Hospital Corporation - Charlestown MA
Northeastern Ohio Universities of Medicine - Rootstown OH

A61K048/00, C12N005/08

424093210, 435368000

One of the impediments to the treatment of some human brain tumors (e.g. gliomas) has been the degree to which they expand, migrate widely, and infiltrate normal tissue. We demonstrate that a clone of multipotent neural progenitor stem cells, when implanted into an experimental glioma, will migrate along with and distribute themselves throughout the tumor in juxtaposition to widely expanding and aggressively advancing tumor cells, while continuing to express a foreign reporter gene. Furthermore, drawn somewhat by the degenerative environment created just beyond the infiltrating tumor edge, the neural progenitor cells migrate slightly beyond and surround the invading tumor border. When implanted at a distant sight from the tumor bed (e.g., into normal tissue, into the contralateral hemisphere, into the lateral ventricles) the donor neural progenitor/stem cells will migrate through normal tissue and specifically target the tumor cells. These results suggest the adjunctive use of neural progenitor/stem cells as a novel, effective delivery vehicle for helping to target therapeutic genes and vectors to invasive brain tumors that have been refractory to treatment.

2012019, Aug 2, 2012

Dec 5, 2011

13/311511

Evan Yale SNYDER - La Jolla CA, US
Rodolfo GONZALEZ - La Jolla CA, US

SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE - La Jolla CA

A61K 31/713, C07K 14/47, C07K 16/18, C40B 30/04, G01N 33/566, C12N 15/85, A61P 35/00, C07H 21/04, C12Q 1/68

514 44 R, 536 235, 530350, 5303898, 5303873, 5303882, 435 611, 436501, 435455, 506 9, 435 71

We have identified ZNF206, a novel repressor of human embryonic stem cell (hESC) differentiation. Repressing extra-embryonic endoderm development preserves the pluripotent state of human embryonic stem cells, and, conversely down-regulating expression of ZNF206 in hESCs causes them to upregulate the expression of genes associated with the extra-embryonic endodermal lineage, down-regulate genes associated with the pluripotent state, and may lead to the further emergence of genes associated with even more differentiated lineages and phenotypes.

2004009, May 13, 2004

Dec 6, 2003

10/344712

Evan Snyder - La Jolla CA, US
Jeanne Loring - Del Mar CA, US
Gary Snable - Atherton CA, US
Karen Aboody - Arcadia CA, US
Marcel Daadi - Palo Alto CA, US

A61K045/00, C12N005/08

435/368000, 424/093700

A method of treating Alzheimer's disease provides for administering NSC to a susceptible individual. Preferably the NSCs are administered intracisternally. Other administration routes are spinal injection, ventricular injection or systemic injection. Preferably, the quantity of NSC administered is in a range of about 400,000 to about 40,000,000. More preferably, the quantity of NSC is about 1,000,000 to about 10,000,000. The NSCs are administered at multiple locations. The NSCs can be administered to the neocortex or other affected areas of both hemispheres. The method of preventing further deterioration in cognitive function in a person diagnosed with Alzheimer's disease provides for administering NSC to the person in sufficient quantity to prevent additional loss of cognitive function.

8071378, Dec 6, 2011

Aug 6, 2008

12/221824

Evan Yale Snyder - La Jolla CA, US
Rodolfo Gonzalez - La Jolla CA, US

Sanford-Burnham Medical Research Institute - La Jolla CA

C12N 5/00, C12N 5/02, C12N 15/00

435377, 435455, 435325

We have identified ZNF206, a novel repressor of human embryonic stem cell (hESC) differentiation. Repressing extra-embryonic endoderm development preserves the pluripotent state of human embryonic stem cells, and, conversely downregulating expression of ZNF206 in hESCs causes them to upregulate the expression of genes associated with the extra-embryonic endodermal lineage, down-regulate genes associated with the pluripotent state, and may lead to the further emergence of genes associated with even more differentiated lineages and phenotypes.

2008018, Jul 31, 2008

Dec 19, 2007

12/004299

Evan Y. Snyder - La Jolla CA, US
Rodolfo Gonzalez - La Jolla CA, US
Jeanne F. Loring - La Jolla CA, US
Prithi Rajan - La Jolla CA, US

The Burnham Institute - La Jolla CA

C12N 5/00, C12N 5/02

435353, 435363, 435404, 4353723, 435395, 435354

An isolated mammalian extraembryonic endoderm-like cell line is provided. Methods for producing isolated mammalian extraembryonic endoderm-like cell line derived from a mammalian pluripotent stem cell culture are provided. Primate or human embryonic stem cells (ESCs) spontaneously generate the primate or human extraembryonic endoderm-like cell line wherein the extraembryonic endoderm-like cells sustain the pluripotence of the primate or human ESCs.

7655224, Feb 2, 2010

Oct 12, 2006

11/546726

Evan Y. Snyder - La Jolla CA, US
Xandra O. Breakefield - Newton Center MA, US
Karen S. Aboody - Arcadia CA, US
Ulrich Herrlinger - Tuebingen, DE
William P. Lynch - Ravenna OH, US

Children's Medical Center Corp. - Boston MA
The General Hospital Corp. - Boston MA
Northeastern Ohio Universities COM - Rootstown OH

A61K 48/00, C12N 15/63, C12N 5/08, A61K 31/70

424 9321, 435455, 4353201, 435368

The present invention is based upon a surprising finding that stem cells, more particularly neural stem cells, can migrate throughout a brain tumor and track metastatic brain tumor cells. The invention provides a method for treating brain tumors by administering genetically engineered neural stem cells in an individual affected by brain tumors. The invention also provides a method of preparing genetically engineered neural stem cells and a composition comprising genetically engineered neural stem cells in a pharmaceutically acceptable carrier.

2011000, Jan 6, 2011

Jun 10, 2010

12/813174

Evan Snyder - San Diego CA, US

Burnham Institute for Medical Research - La Jolla CA

A61K 35/30, C12N 5/00, C12N 5/079, C12Q 1/02, A61P 25/00

424 937, 435377, 435368, 435 29

Disclosed are compositions and methods for producing neural cells from stem cells and uses thereof.